Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Optiscan Imaging's ROE % for the quarter that ended in Dec. 2025 was -45.68%. Optiscan Imaging's PB Ratio for the quarter that ended in Dec. 2025 was 4.76.
Optiscan Imaging's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -9.60%.
Optiscan Imaging ROE % Adjusted to Book Value Related Terms
Optiscan Imaging ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Optiscan Imaging's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Optiscan Imaging ROE % Adjusted to Book Value Chart
ASX:OIL vs COHR, KEYS, GRMN: ROE % Adjusted to Book Value Comparison
For the Scientific & Technical Instruments subindustry, Optiscan Imaging's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Optiscan Imaging ROE % Adjusted to Book Value vs Hardware Industry
For the Hardware industry and Technology sector, Optiscan Imaging's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Optiscan Imaging's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -9.60% mean?
Optiscan Imaging (ASX:OIL) has a ROE % Adjusted to Book Value of -9.60% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Optiscan Imaging and its competitors.
Is Optiscan Imaging's ROE % Adjusted to Book Value too high?
Optiscan Imaging's current ROE % Adjusted to Book Value is -9.60%. Overall, Optiscan Imaging has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Optiscan Imaging's ROE % Adjusted to Book Value compare to COHR and KEYS?
Optiscan Imaging's ROE % Adjusted to Book Value of -9.60% can be compared against companies in the Hardware industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Hardware company?
A good ROE % Adjusted to Book Value depends on the Hardware industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Optiscan Imaging and its competitors. Optiscan Imaging's current ROE % Adjusted to Book Value is -9.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Optiscan Imaging stock overvalued right now?
Based on GuruFocus' analysis, Optiscan Imaging (ASX:OIL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.04, compared to a current price of A$0.15 — trading 262.5% above its estimated fair value. The current ROE % Adjusted to Book Value is -9.60%. Optiscan Imaging's overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Optiscan Imaging (ASX:OIL), the current ROE % Adjusted to Book Value is -9.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Optiscan Imaging (ASX:OIL) Overvalued in 2026?
Based on GuruFocus' analysis, Optiscan Imaging stock appears to be overvalued.
The current stock price of A$0.15 is trading 262.5% above its estimated GF Value™ of A$0.04.
GuruFocus considers Optiscan Imaging to be Significantly Overvalued.
Key valuation signals for ASX:OIL:
ROE % Adjusted to Book Value: -9.60%
GF Value™: A$0.04 vs. price of A$0.15 (262.5% above fair value)
No single metric tells the full story. See the ASX:OIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Optiscan Imaging Ltd is engaged in the development, manufacture, and commercialization of endomicroscopic digital imaging technology solutions for medical, translational, and pre-clinical applications. Its technology offers real-time, 3D, in vivo imaging at the single-cell level, in a non-destructive manner that enables clinicians to make immediate informed decisions. Its products include InVivage, ViewnVivo, and Customisation. Its geographical segments include Australia, Germany, Norway, China, and the United States.
22GF Score
Get the complete analysis for ASX:OIL
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OIL has been successfully added to your 
